title: Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs.
abstract: Quinolone antibacterial drugs inhibit DNA gyrase, a type 2 topoisomerase. Since topoisomerases are present in eukaryotic cells, it was of interest to evaluate the antifungal activities of two clinically available quinolones, ciprofloxacin and trovafloxacin, alone and in combination with amphotericin B or fluconazole, in vitro against Candida albicans and in a murine model of invasive candidiasis. The in vitro activity of trovafloxacin was also tested against other yeasts and molds. In vitro, trovafloxacin exhibited no antifungal activity against any of the fungi (MIC, >250 microg/ml). There was also no effect of the quinolone on the in vitro activity of either antifungal drug. Marked antifungal effects were seen, however, in the murine model of candidiasis. In all experiments, control mice infected intravenously with C. albicans were dead by day 24. While either quinolone had minimal effects on survival of mice when used alone in oral doses of up to 40 mg/kg twice daily, the combination of the quinolone with fluconazole (40 or 80 mg/kg given twice daily by oral gavage) was more effective in prolonging survival than was fluconazole alone. Colony counts of kidneys on days 12 and 30 showed similar reductions in C. albicans recovered from mice treated with fluconazole with or without trovafloxacin or amphotericin B with or without trovafloxacin. Survival of mice treated with a suboptimal dose of amphotericin B (0.2 mg/kg/day) was also improved when trovafloxacin (40 mg/kg) given twice daily was included (0 versus 27%, respectively; P < 0.05). While the mechanisms of action of the combination of trovafloxacin and amphotericin B or fluconazole are unclear, further work focused on fungal topoisomerase inhibition and the mechanism of the antifungal effect of quinolone antibacterial drugs is warranted.
authors.affiliation: Evans Memorial Department of Clinical Research, Boston Medical Center, Massachusetts 02181, USA. asugar@med-med1.bu.edu
authors.forename: A M
authors.initials: AM
authors.lastname: Sugar
authors.forename: X P
authors.initials: XP
authors.lastname: Liu
authors.forename: R J
authors.initials: RJ
authors.lastname: Chen
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000627:therapeutic use*; D024841:Fluoroquinolones; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000627:therapeutic use*; D059005:Topoisomerase II Inhibitors
chemical_list: D000890:Anti-Infective Agents; D000935:Antifungal Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin; D000666:Amphotericin B; D015725:Fluconazole; C080163:trovafloxacin